[The current status of the treatment of tumor lysis syndrome--the role of rasburicase (Fasturtec)].
Urbieta
M
M
Laboratoires Sanofi-Aventis, Paris, France. marisol.urbieta@sanofi-aventis.com
D000493:Allopurinol / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D011994:Recombinant Proteins; D051437:Renal Insufficiency / Q000517:prevention & control; D015275:Tumor Lysis Syndrome / Q000188:drug therapy*; D014503:Urate Oxidase / Q000627:therapeutic use*
D000963:Antimetabolites; D011994:Recombinant Proteins; C469709:rasburicase; D000493:Allopurinol; D014503:Urate Oxidase